Blogs

Categories

Select a Sub-Category

Films and Coatings
Pharmaceutical Packaging Components
Prefillable Systems
Self Injection Devices
Vial Containment Solutions
Washing and Sterilization
Reconstitution and Transfer Devices

Select a Sub-Category

Analytical Lab Services
Contract Manufacturing
Fill-Finish
Regulatory Support

Select a Sub-Category

Cell and Gene Therapy Packaging
Drug Development Process
Regulatory Challenges
Transitioning to Combination Products

Select a Sub-Category

Corporate Development
ESG/Sustainability
One West Team (Employee Culture)
Our Culture of Giving (Philanthropy)
Research and Development

Previous Blogs

Diane Paskiet Presents at Peptalk

By Crystal Kraft, Ph.D.

一月 10, 2017

Critical quality attributes (CQAs) of biologic drug products can be affected by multiple factors throughout the product lifecycle, including the container closure and delivery systems. Diane Paskiet, Director of Scientific Affairs at West Pharmaceutical Services, discussed containment and delivery system compatibility with biologic drug products along with regulatory considerations in her presentation Establishing Safety of Container Closure and Delivery Device Systems at the PepTalk 2017 conference. Evaluating potential impacts early, holistically, and throughout bioprocessing can facilitate decisions at each step that will minimize risks to CQAs and safety.